KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.

Deidre Wilkins, Ulrika Wählby Hamrén, Yue Chang, Lindsay E Clegg, Joseph Domachowske, Janet A Englund, William J Muller, Amanda Leach, Elizabeth J Kelly, Tonya Villafana

Pediatrics 154(5) e2024067174

PMID39350745
PMCID-
DOI10.1542/peds.2024-067174
发表日期2024-10-01
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Data describing respiratory syncytial virus (RSV) neutralizing antibody (nAb) levels for nirsevimab, a recently approved, extended half-life, anti-RSV fusion protein (F protein) monoclonal antibody, relative to the previous standard of care, palivizumab, have not been reported. METHODS: MEDLEY was a randomized, palivizumab-controlled, phase 2/3 study of nirsevimab during 2 RSV seasons (season 1 and 2) in infants born preterm (≤35 weeks' gestational age; dosed season 1 only) or with congenital heart disease or chronic lung disease of prematurity (dosed seasons 1 and 2). Participants were randomly assigned to receive a single dose of nirsevimab followed by 4 monthly placebo doses, or 5 once-monthly doses of palivizumab. Anti-RSV F protein serology (ie, levels of prefusion [pre-F]/postfusion [post-F] conformation antibodies), nirsevimab and palivizumab concentrations, and RSV nAbs were measured in participant serum collected at baseline (pre-dose) and days 31, 151, and 361. RESULTS: Serologic data were similar in seasons 1 and 2. Nirsevimab predominately conferred pre-F antibodies, whereas palivizumab conferred pre-F and post-F antibodies. Nirsevimab and palivizumab serum concentrations highly correlated with nAb levels in both seasons. In season 1, nAb levels in nirsevimab recipients were highest in day 31 samples and gradually declined but remained 17-fold above baseline at day 361. nAb levels in palivizumab recipients increased incrementally with monthly doses to day 151. nAb levels followed similar patterns in season 2. nAb levels were ∼10-fold higher with nirsevimab compared with palivizumab across both seasons. CONCLUSIONS: Nirsevimab prophylaxis confers ∼10-fold higher and more sustained RSV nAb levels relative to palivizumab.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。